Accessibility Menu
 
Arrow-Thin-Down
S&P 500
6,556.37
-0.4%
-24.63
Arrow-Thin-Down
DJI
46,124.06
-0.2%
-84.41
Arrow-Thin-Down
NASDAQ
21,761.89
-0.8%
-184.87
Arrow-Thin-Down
Bitcoin
$71,552.00
+0.4%
+$314.01
Arrow-Thin-Down
AMZN
$207.10
-1.4%
-$3.04
Arrow-Thin-Down
GOOG
$289.30
-3.3%
-$9.72
Arrow-Thin-Down
META
$592.51
-1.9%
-$11.55
Arrow-Thin-Down
MSFT
$372.37
-2.8%
-$10.63
Arrow-Thin-Down
NVDA
$175.20
-0.3%
-$0.44
Arrow-Thin-Down
TSLA
$383.03
+0.6%
+$2.18
Most Active StocksDaily Stock GainersDaily Stock Losers

This Biotech's Run Is Far From Done

Two pieces of news that show Gilead still has plenty of room to run.

By Dave Williamson – Mar 5, 2013 at 5:48PM EST

In the following video, Motley Fool health-care analyst David Williamson looks at two major pieces of news surrounding biotech company Gilead (GILD +0.51%) that show that the company has a bright future ahead. He discusses another 100% cure rate for the company in the hepatitis-C space, and a new once-daily HIV drug for the company, with a better safety profile than the competition.

Read Next

About the Author

Dave Williamson
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
XMFGreenwave4
X@motleydavid

Stocks Mentioned

Gilead Sciences Stock Quote
Gilead Sciences
NASDAQ: GILD
$138.04
(+0.51%)+$0.70
Johnson & Johnson Stock Quote
Johnson & Johnson
NYSE: JNJ
$235.00
(-0.18%)-$0.42
Bristol Myers Squibb Stock Quote
Bristol Myers Squibb
NYSE: BMY
$57.39
(+0.68%)+$0.39

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services